Observational Health Data Sciences and Informatics

User Tools

Site Tools

Trace: • celecoxib_vs_nsnsaids
research:comparison_of_combination_treatment_in_hypertension

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
research:comparison_of_combination_treatment_in_hypertension [2017/04/16 08:54] – burculantonijaresearch:comparison_of_combination_treatment_in_hypertension [2017/08/07 08:42] (current) – [Discussion] scyou
Line 1: Line 1:
-====== Large-scale modeling of patients with thyroid conditions ======+====== Comparison of combination treatment in hypertension ======
  
 <WRAP box justify round> <WRAP box justify round>
  
-**Objective:** //Characterisation of non-cancerous thyroid disorder population and sources of variation within treatment pathways//+**Objective:** The goal of this protocols is conducting comparative effectiveness research to establish evidences for optimal anti-hypertensive combination strategies among patients without cardiovascular outcome from various databases across world.
  
-**Rationale:** //The goal of antihypertensive therapy is to reduce cardiovascular end points including stroke, myocardial infarction, and heart failure by lowering blood pressure. Although it is evident that BP reduction per se is the primary determinant of CV risk reduction, the choice of initial drug therapy can exert some effect on long-term outcomes. Many large randomized trials have shown that two or more antihypertensive agents are required for reaching their treatment goals. Furthermore, recent data have suggested that the use of combination therapy in patients with hypertension may be beneficial for blood-pressure-lowering efficacy, obtaining blood pressure goals earlier, and reducing major adverse cardiovascular events. To date, However, the best combination treatment in hypertension have not been demonstrated. The evidence through OHDSI network can help clinicians to select the combination treatment for their patients.//+**Rationale:** High blood pressure is the leading global burden of death and disability. Extensive evidences support the beneficial effects in tight control of blood pressure. Since monotherapy is often insufficient or slow to reach blood pressure target quickly, combination therapy is recommended as the first-line treatment for selected patients with hypertension by the recent guideline to reduce cardiovascular risk. Retrospective observational studies and meta-analysis have suggested that initial combination hypertensive treatment confers decreased risk for cardiovascular events than monotherapy. Only a few randomized clinical trials, however, have directly compared the effects of different regimens of combination. In addition to limited number of evidences from head-to-head comparison, baseline high risk for cardiovascular outcome and previous history of anti-hypertensive medication of participants also make the findings from RCTs difficult to apply to clinical practice. To the best of our knowledge, real-world comparative effectiveness research comparing the various regimens of combination treatment in patients with essential hypertension has not been conducted until now. 
  
-**Project Lead(s):** //Seng Chan You, Sungjae Jung, and Rae Woong Park from Ajou university// 
  
-**Coordinating Institution(s):** //Ajou university//+**Project Lead(s):** 
 +Seng Chan You, MD, Ajou University, Korea 
 +Sungjae Jung, BE, Ajou University, Korea 
 +Sungha Park, MD, Yonsei university College of Medicine, Korea 
 +Rae Woong Park, MD, PhD, Ajou University, Korea
  
-** Additional Participants:**  // //+**Coordinating Institution(s):** Ajou University, Korea
  
-**Full Protocol:** //[[https://github.com/OHDSI/StudyProtocolSandbox/raw/master/HypertensionCombination/documents/HTN_combi_protocol_ver0.3(17.1.2).docx|Word doc for the protocol]] //+** Additional Participants:**  //  
 + // 
 + 
 +**Full Protocol:** [[https://github.com/OHDSI/StudyProtocolSandbox/blob/master/HypertensionCombination/documents/HTN_combi_protocol_ver1.1.docx|Word doc for the protocol]] 
  
 **Initial Proposal Date:** Sep 2016   **Initial Proposal Date:** Sep 2016  
  
-**Launch Date:** 16 Jan 2017  // //+**Launch Date:** 7 Aug 2017
  
 **Study Closure Date:  // //** **Study Closure Date:  // //**
  
-**Results Submission:** //<method of sumission,  [[mailto:[email protected]|Email]]>//+**Results Submission:** Via Google Drive
  
 </WRAP> </WRAP>
  
 ===== Requirements ===== ===== Requirements =====
-**CDM:** //V5 only//+**CDM:** V5 or over
  
-**Table Accessed:**  //person, drug_exposure, drug_era, death, condition_occurrence, measurement, procedure_occurrence, visit_occurrence//+**Table Accessed:**  person, drug_exposure, drug_era, death, condition_occurrence, procedure_occurrence, visit_occurrence
  
 **Database Dialects:** SQL Server, Postgres, Oracle **Database Dialects:** SQL Server, Postgres, Oracle
  
-**Software:**  //R// +**Software:**  R
    
 ===== Code =====  ===== Code ===== 
Line 38: Line 44:
  
 ===== Discussion =====  ===== Discussion ===== 
-//Post a thread letting everyone know about this new proposed study at [[http://forums.ohdsi.org/c/researchers]]// +//[[http://forums.ohdsi.org/c/researchers]]// 
  
 ===== Datasets Run =====  ===== Datasets Run ===== 
research/comparison_of_combination_treatment_in_hypertension.1492332897.txt.gz · Last modified: by burculantonija
Donate Powered by PHP Valid HTML5 Valid CSS Driven by DokuWiki